Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.55 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.51 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7846994 | 0.98 | IRAK4 (0.96) | IRAK4HTTCTNNB1MKNK1MKNK2 | |
| SCHEMBL11768273 | 0.87 | IRAK4 (0.77) | IRAK4HTTCTNNB1ALDH1A1MAPT | |
| SCHEMBL5887079 | 0.87 | IRAK4 (0.77) | IRAK4HTTCTNNB1ALDH1A1MAPT | |
| SCHEMBL10407490 | 0.85 | IRAK4 (0.74) | IRAK4HTTCTNNB1ALDH1A1MAPT | |
| SCHEMBL28124500 | 0.85 | IRAK4 (0.74) | IRAK4HTTCTNNB1ALDH1A1MAPT | |
| SCHEMBL28294074 | 0.85 | IRAK4 (0.74) | IRAK4HTTCTNNB1ALDH1A1MAPT | |
| SCHEMBL7088362 | 0.84 | IRAK4 (0.72) | IRAK4ALDH1A1KMT2AACHELMNA | |
| SCHEMBL2094692 | 0.84 | IRAK4 (0.72) | IRAK4ALDH1A1MAPTKMT2AACHE | |
| SCHEMBL8386891 | 0.84 | IRAK4 (0.72) | IRAK4HTTCTNNB1MKNK1MKNK2 | |
| SCHEMBL27370629 | 0.84 | IRAK4 (0.72) | IRAK4HTTCTNNB1MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008071453-A1 | 1,2-DIARYLACETYLENE DERIVATIVES OF ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-19 | — | — | WO | claimed |
| EP-1037633-B1 | ANTIVIRAL COMPOUNDS | IAF BIOCHEM INT (CA) | 2003-09-10 | — | — | EP | claimed |
| EP-1155017-B1 | [1,8] NAPHTHYRIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | SHIRE BIOCHEM INC (CA) | 2003-01-15 | — | — | EP | claimed |
| JP-2002532415-A | — | — | 2002-10-02 | — | — | JP | claimed |
| EP-1143957-A3 | TREATMENT OF ARTHRITIS WITH MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-02-27 | — | — | EP | claimed |
| EP-1143957-A2 | TREATMENT OF ARTHRITIS WITH MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-10-17 | — | — | EP | claimed |
| EP-1140067-A1 | ANTIVIRAL METHOD USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-10-10 | — | — | EP | claimed |
| EP-1102769-A2 | TRICYCLIC CARBOXAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2001-05-30 | — | — | EP | claimed |
| WO-2000040237-A1 | ANTIVIRAL METHOD USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-13 | — | — | WO | claimed |
| WO-2000035436-A2 | TREATMENT OF ARTHRITIS WITH MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-06-22 | — | — | WO | claimed |
| CN-1255124-A | Substituted isoquinoline derivatives and their use as anticonulsants | SMITHKLINE BEECHAM PLC (GB) | 2000-05-31 | — | — | CN | claimed |
| WO-2000008020-A2 | TRICYCLIC CARBOXAMIDES | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-02-17 | — | — | WO | claimed |
| WO-2024206284-A2 | THERAPEUTIC COMPOUNDS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-10-03 | — | — | WO | disclosed |
| US-20230255906-A1 | Targeting Serpin B9 in Cancer | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-08-17 | — | — | US | disclosed |
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| EP-3350184-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | LOXO ONCOLOGY INC (US) | 2022-10-19 | — | — | EP | disclosed |
| US-4983600-A | Antiemetics, antianxiety agents, gastrointestinal disorders | JOHN WYETH & BROTHER LIMITED (GB) | 1991-01-08 | — | — | US | disclosed |
| EP-0323077-A1 | Heterocyclic compounds | JOHN WYETH & BROTHER LIMITED (GB) | 1989-07-05 | — | — | EP | disclosed |
| US-4082751-A | ANTIALLERGENS | BRISTOL-MYERS COMPANY (US) | 1978-04-04 | — | — | US | disclosed |
| US-4031093-A | ANTIALLERGENS | BRISTOL-MYERS COMPANY (US) | 1977-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | IRAK4 98/4885HTT 2427/4885CTNNB1 2299/4885 |
| US-20230255906-A1 | Targeting Serpin B9 in Cancer | SERPINB10, SERPINB8, SERPINE1 | IRAK4 3024/4885HTT 1136/4885CTNNB1 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.